Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome
- PMID: 32483543
- PMCID: PMC7231748
- DOI: 10.5223/pghn.2020.23.3.189
Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome
Abstract
The metabolic syndrome, by definition, is not a disease but is a clustering of individual metabolic risk factors including abdominal obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low high-density lipoprotein cholesterol levels. These risk factors could dramatically increase the prevalence of type 2 diabetes and cardiovascular disease. The reported prevalence of the metabolic syndrome varies, greatly depending on the definition used, gender, age, socioeconomic status, and the ethnic background of study cohorts. Clinical and epidemiological studies have clearly demonstrated that the metabolic syndrome starts with central obesity. Because the prevalence of obesity has doubly increased worldwide over the past 30 years, the prevalence of the metabolic syndrome has markedly boosted in parallel. Therefore, obesity has been recognized as the leading cause for the metabolic syndrome since it is strongly associated with all metabolic risk factors. High prevalence of the metabolic syndrome is not unique to the USA and Europe and it is also increasing in most Asian countries. Insulin resistance has elucidated most, if not all, of the pathophysiology of the metabolic syndrome because it contributes to hyperglycemia. Furthermore, a major contributor to the development of insulin resistance is an overabundance of circulating fatty acids. Plasma fatty acids are derived mainly from the triglycerides stored in adipose tissues, which are released through the action of the cyclic AMP-dependent enzyme, hormone sensitive lipase. This review summarizes the latest concepts in the definition, pathogenesis, pathophysiology, and diagnosis of the metabolic syndrome, as well as its preventive measures and therapeutic strategies in children and adolescents.
Keywords: Diabetes; Dyslipidemia; Hyperglycemia; Insulin resistance; Obesity.
Copyright © 2020 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition.
Conflict of interest statement
Conflicts of Interest: The authors have no financial conflicts of interest.
Figures



References
-
- Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428. - PubMed
-
- Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014;43:1–23. - PubMed
-
- Dommermuth R, Ewing K. Metabolic syndrome: systems thinking in heart disease. Prim Care. 2018;45:109–129. - PubMed
-
- Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, et al. The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome. J Am Coll Cardiol. 2015;66:1050–1067. - PubMed
-
- D'Adamo E, Marcovecchio ML, Giannini C, Capanna R, Impicciatore M, Chiarelli F, et al. The possible role of liver steatosis in defining metabolic syndrome in prepubertal children. Metabolism. 2010;59:671–676. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous